Enter Note Done
Go to previous page in this tab
Event
  • Scientific Session
  • Bookmark Icon
  • Complementary In Vitro and In Vivo Approaches to Address Emerging Inhaled Pollutants: E-cigarette Aerosols, Microplastics, and Air Pollution
  • Schedule
    Notes
  • Stars at Night Ballroom B4‚ Convention Center
    Set Timezone


Chair: Alexandra Noël, Louisiana State University
Co-Chair: Xiaojia He, UL Research Institutes' Chemical Insights

Primary Endorser: Nanoscience and Advanced Materials Specialty Section


Endorser(s): Inhalation and Respiratory Specialty Section


Endorser(s): Exposure Specialty Section


Regulatory agencies in the United States have mandated reduction of animal/in vivo studies, which led to the accelerated development and validation of new alternative methodologies (NAMs). This regulatory imperative highlights the urgent need for NAMs specifically designed for inhalation studies. This session will focus on novel complementary in vitro and in vivo studies in inhalation toxicology and bring together experts to bridge the gap between traditional animal testing and modern, human-relevant alternatives. Indeed, the demand for NAMs in inhalation toxicology research is increasing to ensure mechanistic understanding and translational impact. NAMs can also be used to model metabolism and toxicokinetics in the lungs to predict how inhaled pollutants are bio-transformed and distributed. Despite NAMs many promises, significant barriers to NAMs adoption in inhalation toxicology have been identified. Major challenges include constraints in addressing repeated-dose, chronic toxicity, dosimetry, and characterization of complex inhaled mixtures for realistic exposure scenario modeling. In contrast, advantages of in vivo animal models include cohesive physiological responses. Comparative studies directly linking in vitro air-liquid interface (ALI) and advanced 3-D model responses to validated in vivo outcomes remain a priority.

Overall, integration and complementarity of in vitro and in vivo approaches can provide strong evidence base for risk assessment and regulatory decision-making of emerging inhaled pollutants. This need has become increasingly vital due to the rapid increase in e-cigarette use among adolescents and adults, the widespread presence of micro/nanoplastics in human tissues and biological fluids, and the intensification of air pollution associated with climate change. Increasing evidence demonstrates that emerging inhaled pollutants are associated with complex and potentially long-term health effects. Recent omics approaches, including transcriptomics and proteomics, have identified key molecular pathways and signaling networks implicated in e-cigarette-induced cardiovascular injury, micro/nanoplastic-associated toxicity, and air pollution-driven pulmonary inflammation. At the same time, advances in analytical and spectroscopic technologies have confirmed widespread human exposure to micro/nanoplastics through multiple routes, including inhalation. Although significant progress has been made, several difficulties persist in the field of inhalation toxicology research. The rapidly evolving diversity of e-cigarette devices and e-liquid formulations creates highly variable exposure scenarios that complicate toxicological evaluation. Similarly, micro/nanoplastics research is limited by difficulties in modeling environmentally relevant chronic low-dose exposures, while air pollution-related toxicity can vary substantially depending on source and composition, including diesel exhaust, wildfire-derived, and climate-related particulate emissions. This session will bring together toxicologists and environmental health scientists, with expertise, among others, in molecular biology and biochemistry, to discuss and present complementary in vitro and in vivo approaches for evaluating emerging inhaled pollutants. The intended audience includes inhalation researchers, scientists specializing in NAMs, as well as regulatory toxicologists in governmental agencies and in the industry, involved with evaluation of inhaled compounds.

Speakers in this session will highlight how integrated experimental frameworks can improve mechanistic understanding, enhance physiological relevance, and strengthen translation of findings to human health outcomes and regulatory science applications. Using e-cigarette aerosols, flame-retardant polyester fibers (microplastics), and air pollution (diesel exhaust particles) as representative exposure scenarios, in addition to deepening our understanding of how NAMs can be used to assess the toxicokinetics of inhaled pollutants, this session will demonstrate how coordinated in vitro and in vivo strategies can address key methodological and translational challenges in modern inhalation toxicology. Thus, key objectives and takeaways are to: (1) showcase current in vitro and in vivo methodologies for assessing toxicity of emerging inhaled pollutants; (2) identify complementary strengths and limitations of cellular and animal models; and (3) highlight how to bridge preclinical research and human outcomes. By bringing together diverse expertise and facilitating transparent discussion of methodological challenges and regulatory science needs, this session will highlight the potential gain of harmonizing in vitro and in vivo approaches in inhalation toxicology.

Session and Activity Type
Presentations